{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:51Z","timestamp":1792791951328,"version":"4.5.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Comit\u00e9 D\u00e9partemental De Lutte Contre Les Maladies Respiratoires"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The treatment of <jats:italic>Mycobacterium avium<\/jats:italic> infections is still long, complex, and often poorly tolerated, besides emergence of resistances. New active molecules that are more effective and better tolerated are deeply needed. Mefloquine and its enantiomers ((+) Erythro-mefloquine ((+)-EMQ) and (-)-Erythro-mefloquine ((-)-EMQ)) have shown efficacy in both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, in a mouse model of <jats:italic>M<\/jats:italic>. <jats:italic>avium<\/jats:italic> intraveinous infection. However, no study reports aerosol model of infection or combination with gold standard treatment. That was the aim of our study. In an aerosol model of <jats:italic>M<\/jats:italic>. <jats:italic>avium<\/jats:italic> infection in BALB\/c mice, we used five treatment groups as followed: Clarithromycin-Ethambutol-Rifampicin (CLR-EMB-RIF, standard of care, n = 15), CLR-EMB-MFQ (n = 15), CLR-EMB-(+)-EMQ (n = 15), CLR-EMB-(-)-EMQ (n = 15) and an untreated group (n = 25). To evaluate drug efficacy, we sacrificed each month over 3 months, 5 mice from each group. Lung homogenates were diluted and plated for colony forming unit count (CFU) expressed in Log10. At each time point, we found a significant difference between the untreated group and each of the treatment groups (p&lt;0.005). The (+)-EMQ-CLR-EMB group was the group with the lowest CFU count at each time point but never reached statistical significance. The results of each group 3 months after treatment are: (+)-EMQ-CLR-EMB (4.43 \u00b1 0.26), RIF-CLR-EMB (4.83 \u00b1 0.37), (-)-EMQ-CLR-EMB (4.82 \u00b1 0.18), MFQ-CLR-EMB (4.70 \u00b1 0.21). In conclusion, MFQ and its enantiomers appear to be as effective as rifampicin in combination therapy. Further studies are needed to evaluate the ability of these drugs to prevent selection of clarithromycin resistant strains and potential for lung sterilization.<\/jats:p>","DOI":"10.1371\/journal.pone.0311167","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:27:06Z","timestamp":1727717226000},"page":"e0311167","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5185-8590","authenticated-orcid":true,"given":"Antoine","family":"Froment","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Delomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Da Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dassonville-Klimpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Andr\u00e9jak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Sonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Lanoix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"pone.0311167.ref001","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/infdis\/jiaa354","article-title":"Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management","volume":"222","author":"CL Daley","year":"2020","journal-title":"J Infect Dis"},{"key":"pone.0311167.ref002","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3349\/ymj.2010.51.6.888","article-title":"Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease","volume":"51","author":"YS Sim","year":"2010","journal-title":"Yonsei Med J"},{"key":"pone.0311167.ref003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4046\/trd.2018.0060","article-title":"Treatment of Mycobacterium avium Complex Pulmonary Disease","volume":"82","author":"YS Kwon","year":"2019","journal-title":"Tuberc Respir Dis"},{"key":"pone.0311167.ref004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jiac.2020.02.008","article-title":"Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"26","author":"Y Adachi","year":"2020","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"pone.0311167.ref005","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jiac.2019.05.028","article-title":"Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan","volume":"25","author":"Y Yamaba","year":"2019","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"pone.0311167.ref006","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jiac.2017.10.022","article-title":"Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens","volume":"24","author":"EH Cho","year":"2018","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"key":"pone.0311167.ref007","first-page":"e02349","article-title":"Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection","volume":"64","author":"J-P Lanoix","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0311167.ref008","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.04841-14","article-title":"Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations","volume":"59","author":"C Andr\u00e9jak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0311167.ref009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0041-3879(89)90020-2","article-title":"The beige mouse model for Mycobacterium avium complex (MAC) disease: optimal conditions for the host and parasite","volume":"70","author":"PR Gangadharam","year":"1989","journal-title":"Tubercle"},{"key":"pone.0311167.ref010","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1086\/587906","article-title":"The efficacy of clarithromycin and the bicyclolide EDP-420 against Mycobacterium avium in a mouse model of pulmonary infection","volume":"197","author":"LE Bermudez","year":"2008","journal-title":"J Infect Dis"},{"key":"pone.0311167.ref011","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1164\/ajrccm\/139.5.1098","article-title":"Susceptibility of beige mice to Mycobacterium avium complex infections by different routes of challenge","volume":"139","author":"PR Gangadharam","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"pone.0311167.ref012","unstructured":"Dassonville-Klimpt A, Jonet A, Pillon M, Mulli\u00e9 C, Sonnet P. Mefloquine derivatives: synthesis, mechanisms of action, antimicrobial activities. 2011."},{"key":"pone.0311167.ref013","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/cplu.201300074","article-title":"Absolute Configuration and Antimalarial Activity of erythro-Mefloquine Enantiomers","volume":"78","author":"A Dassonville-Klimpt","year":"2013","journal-title":"ChemPlusChem"},{"key":"pone.0311167.ref014","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ejmech.2010.01.024","article-title":"Novel quinoline and naphthalene derivatives as potent antimycobacterial agents","volume":"45","author":"RS Upadhayaya","year":"2010","journal-title":"Eur J Med Chem"},{"key":"pone.0311167.ref015","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.3390\/ijms22168533","article-title":"The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism","volume":"22","author":"G Degiacomi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0311167.ref016","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Mefloquine is active in vitro and in vivo against Mycobacterium avium complex","volume":"43","author":"LE Bermudez","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0311167.ref017","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00320-12","article-title":"Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice","volume":"56","author":"LE Bermudez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0311167.ref018","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.36.9.2066","article-title":"Bioavailability of rifampin in experimental murine tuberculosis","volume":"36","author":"J Dickinson","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0311167.ref019","first-page":"118","article-title":"Rates and risk factors for discontinuation of rifampicin","volume":"4","author":"SV Cook","year":"2000","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"key":"pone.0311167.ref020","doi-asserted-by":"crossref","first-page":"11275","DOI":"10.1038\/s41598-023-38394-1","article-title":"Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis","volume":"13","author":"H-J Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"Suppl 3","key":"pone.0311167.ref021","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/clinids\/5.Supplement_3.S440","article-title":"Adverse effects of rifampin","volume":"5","author":"J Grosset","year":"1983","journal-title":"Rev Infect Dis"},{"key":"pone.0311167.ref022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/3.2.115","article-title":"Adverse reactions to rifampicin in antituberculosis regimens","volume":"3","author":"DJ Girling","year":"1977","journal-title":"J Antimicrob Chemother"},{"key":"pone.0311167.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002280050240","article-title":"Neuro-psychiatric effects of antimalarials","volume":"52","author":"MM van Riemsdijk","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0311167.ref024","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jps.2600830613","article-title":"Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple doses","volume":"83","author":"F Gimenez","year":"1994","journal-title":"J Pharm Sci"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T17:27:23Z","timestamp":1727717243000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311167"}},"subtitle":[],"editor":[{"given":"Delphi","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311167","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}